Nurix Therapeutics (NRIX) legal chief sells exercised shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics Chief Legal Officer Christine Ring exercised stock options and sold the resulting shares in a pre-planned trade. On the reported date, she exercised options for 28,935 shares of common stock at strike prices of $8.72 and $7.26 per share and sold 28,935 shares in open-market transactions at a weighted average price of $20.0624 per share, pursuant to a Rule 10b5-1 trading plan. Following these transactions, the filing reports that she holds 13,579 shares of common stock directly and continues to hold employee stock options, including 134,398 options with a $8.72 exercise price expiring in 2034.

Insider Trade Summary 10b5-1

Net Seller: 28,935 shares ($580,506)

Net Sell 5 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 28,935 shs ($581K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	13,333	$0.00	--
Exercise	Employee Stock Option (right to buy)	15,602	$0.00	--
Exercise	Common Stock	13,333	$7.26	$97K
Exercise	Common Stock	15,602	$8.72	$136K
Sale	Common Stock	28,935	$20.0624	$581K

Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 26,912 shares (Direct, null)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.40. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. The stock option vested as to 1/48 of the total shares monthly beginning February 18, 2020, until the option was fully vested on January 18, 2024. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027.

Key Figures

Shares sold: 28,935 shares Weighted average sale price: $20.0624 per share Options exercised: 28,935 shares +4 more

7 metrics

Shares sold 28,935 shares Open-market sale of common stock

Weighted average sale price $20.0624 per share Common stock sales on transaction date

Options exercised 28,935 shares Total shares from option exercises (codes M)

Strike price 1 $8.72 per share 15,602-share employee stock option exercised

Strike price 2 $7.26 per share 13,333-share employee stock option exercised

Shares held after sale 13,579 shares Direct common stock ownership following transactions

Remaining options 134,398 options Employee stock options at $8.72 exercise price expiring 2034

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy, weighted average sale price, vested, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy financial

"Employee Stock Option (right to buy) listed as a derivative security with underlying common stock."

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price was $20.40."

vested financial

"The stock option vested as to 1/48 of the total shares monthly beginning February 18, 2020, until the option was fully vested on January 18, 2024."

derivative security financial

"Transaction code description refers to Exercise or conversion of derivative security."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:38 PM Accepted by SEC EDGAR 06/25/2026 - 06:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/25/2026		M⁽¹⁾		13,333	A	$7.26	26,912	D
Common Stock	06/25/2026		M⁽¹⁾		15,602	A	$8.72	42,514	D
Common Stock	06/25/2026		S⁽¹⁾		28,935	D	$20.0624⁽²⁾	13,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$7.26	06/25/2026		M⁽¹⁾			13,333	⁽³⁾	02/26/2030	Common Stock	13,333	$0	0	D
Employee Stock Option (right to buy)	$8.72	06/25/2026		M⁽¹⁾			15,602	⁽⁴⁾	02/12/2034	Common Stock	15,602	$0	134,398	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.40. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. The stock option vested as to 1/48 of the total shares monthly beginning February 18, 2020, until the option was fully vested on January 18, 2024.

4. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Nurix Therapeutics (NRIX) report for Christine Ring?

Nurix Therapeutics reported that Chief Legal Officer Christine Ring exercised options for 28,935 shares of common stock and sold 28,935 shares in open-market transactions. These trades were executed under a previously adopted Rule 10b5-1 trading plan, indicating a pre-planned liquidity event.

At what prices did Christine Ring sell Nurix Therapeutics (NRIX) shares?

The filing shows a weighted average sale price of $20.0624 per share for 28,935 Nurix Therapeutics shares. Footnotes state individual sale prices ranged from $20.00 to $20.40, and detailed price breakdowns are available upon request from the company, regulators, or stockholders.

What stock options did Christine Ring exercise in this Nurix Therapeutics (NRIX) Form 4?

Christine Ring exercised employee stock options covering 15,602 shares at a $8.72 exercise price and 13,333 shares at a $7.26 exercise price. These options had vested over time according to monthly vesting schedules that began in February 2020 and March 2024, respectively.

How many Nurix Therapeutics (NRIX) shares does Christine Ring hold after these transactions?

After the reported transactions, the Form 4 shows Christine Ring directly holding 13,579 shares of Nurix Therapeutics common stock. She also retains employee stock options, including 134,398 options with an $8.72 exercise price that remain outstanding and are scheduled to expire in 2034.

Was the Nurix Therapeutics (NRIX) insider stock sale by Christine Ring pre-planned?

Yes. A footnote explains that the stock sale was effected pursuant to a previously adopted Rule 10b5-1 trading plan. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary trading decisions based on short-term market conditions.